Lexeo Therapeutics, Inc.
lexeotx.comLexeo Therapeutics (NASDAQ: LXEO) is a clinical-stage gene therapy company focused on developing adeno-associated virus (AAV)-based treatments for genetic diseases, with a lead program targeting PKP2-arrhythmogenic cardiomyopathy (PKP2-ACM). The company generates no product revenue. Operations are funded entirely through equity issuances, including convertible preferred stock, common stock, pre-funded warrants, and warrants, as disclosed in the 10-K filed March 30, 2026. As of December 31, 2025, Lexeo held approximately $182.0 million in U.S. federal net operating loss carryforwards and $362.9 million in state and local NOLs, reflecting cumulative operating losses since inception. The lead candidate, LX2020, showed dose-dependent increases in PKP2 protein expression averaging 93% in low-dose and 162% in high-dose cohorts at three months across biopsied participants, based on data through January 2026. Net cash used in operating activities was $98.6 million in FY2025 versus $81.2 million in FY2024. CEO R. Nolan Townsend leads the company.
Products & Services
LX2020: AAV-based gene therapy for PKP2-arrhythmogenic cardiomyopathy, in clinical-stage development as of January 2026 readout.
Revenue Model
No product revenue as of the 10-K filed March 30, 2026. Operations funded through equity capital raises, including common stock and warrant issuances.
Customers & Markets
No commercial customers as of the 10-K filed March 30, 2026. End market is patients with genetic cardiac diseases, specifically PKP2-ACM. Counterparties include contract research organizations (CROs) and contract manufacturing organizations (CMOs) for preclinical and clinical development activities.
Geographic Exposure
Operations based in the United States. Clinical and regulatory activities reference FDA jurisdiction primarily, with GDPR compliance noted for EEA and UK data handling.
Financial Snapshot
Loading...
